Sacubitril/valsartan is an angiotensin receptor neprilysin inhibitor (ARNI) that has been shown in multiple clinical trials to have clinical benefits and is recommended by major clinical management guidelines as a first-line treatment for heart failure with reduced ejection fraction (HFrEF). The most significant benefit that was observed in clinical trials is its effect in reducing hospital readmissions. However, little evidence supports its effectiveness in practice, especially in Saudi Arabia. A multicenter retrospective cohort study was conducted using the patient medical records at 2 tertiary hospitals in Saudi Arabia. Eligible patients were adults (≥18 years old) with a confirmed diagnosis of HFrEF who were discharged on either sacubitril/valsartan or angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) in addition to the other recommended therapy for HFrEF. The primary endpoint was the all-cause 30-day readmission rate. The secondary endpoints included all-cause readmissions at 60-day, 90-day, and 12 months. Additionally, 30-day, 60-day, and 90-day readmissions due to HF were evaluated. A total of 398 patients were included in our analysis; 199 (50.0%) received sacubitril/valsartan (group 1), and 199 (50.0%) received ACEI/ARB (group 2). Our results showed that all-cause 30-day readmissions in group 1 were significantly lower than in group 2 (7% vs 25.0%, RR 0.28, 95% Cl 0.16-0.49; P < .001). Additionally, the secondary outcomes showed significantly fewer 60-day, 90-day, and 12-month all-cause readmissions were identified in group 1 compared to group 2 (11% vs 30.7%, RR 0.36, 95% CI 0.23-0.56; P < .001), (11.6%. vs 32.6%, RR 0.35, 95% CI 0.23-0.55; P < .001) and (23.6% vs 51.2%, RR 0.46, 95% CI 0.35-0.62; P < .001), respectively. Furthermore, HF readmissions at 30-day, 60-day, and 90-day in group 1 were significantly lower than in group 2 (P < .05). Sacubitril/valsartan for the treatment of HFrEF is associated with a significantly lower rate of all-cause readmission as well as HF readmissions compared to ACEI/ARB. These benefits extend up to 12 months post-discharge.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11272236 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000038960 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patent ductus arteriosus closure in infants weighing less than 1500 g via a tiny microcatheter: a simple technique with zero-contrast exposure.
Cardiol Young
January 2025
Pediatric Cardiology, Stead Family Children's Hospital, University of Iowa, Iowa City, IA, USA.
Background: Despite patent ductus arteriosus closure in premature infants is a relatively fast procedure, it involves specific steps for equipment exchange and the use of a 4-Fr catheter, which may be large for tiny infants, potentially causing haemodynamic instability or tricuspid valve regurgitation.
Objectives: This study aims to describe the early experience with a new technique designed to simplify transcatheter patent ductus arteriosus closure in premature infants. It enables the closure using the KA micro plug device via a single microcatheter without equipment exchanges and contrast exposure.
On some integral inequalities of Grüss type involving the generalized fractional Saigo -integral operator.
Heliyon
January 2025
Department of Mathematics, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu 602105, India.
Using the generalized Saigo fractional integral operator, the authors of this study prove several novel fractional integral inequalities of the Grüss type. By fixing the values of functions, specific situations derived from previously established findings are shown. The ultimate purpose of this work is to investigate the Grüss-type integral inequalities with the Saigo -integral operator, a more generalized integral operator.
View Article and Find Full Text PDFLarge annotated ultrasound dataset of non-alcoholic fatty liver from Saudi hospitals for analysis and applications.
Data Brief
February 2025
College of Science and Engineering, Hamad Bin Khalifa University, Doha, Qatar.
This study presents a comprehensive ultrasound image dataset for Non-Alcoholic Fatty Liver Disease (NAFLD), addressing the critical need for standardized resources in AI-assisted diagnosis. The dataset comprises 10,352 high-resolution ultrasound images from 384 patients collected at King Saud University Medical City and National Guard Health Affairs in Saudi Arabia. Each image is meticulously annotated with NAFLD Activity Score (NAS) fibrosis staging and steatosis grading based on corresponding liver biopsy results.
View Article and Find Full Text PDFA cross-sectional study of parental perspectives on children about COVID-19 and classification using machine learning models.
Front Public Health
January 2025
Triveni Rai Kisan Mahila Mahavidyalaya, D. D. U. Gorakhpur University, Kushinagar, India.
Background And Objective: This study delves into the parenting cognition perspectives on COVID-19 in children, exploring symptoms, transmission modes, and protective measures. It aims to correlate these perspectives with sociodemographic factors and employ advanced machine-learning techniques for comprehensive analysis.
Method: Data collection involved a semi-structured questionnaire covering parental knowledge and attitude on COVID-19 symptoms, transmission, protective measures, and government satisfaction.
Biophysics-guided uncertainty-aware deep learning uncovers high-affinity plastic-binding peptides.
Digit Discov
January 2025
Department of Chemical and Biomolecular Engineering, North Carolina State University Raleigh North Carolina 27606 USA
Plastic pollution, particularly microplastics (MPs), poses a significant global threat to ecosystems and human health, necessitating innovative remediation strategies. Biocompatible and biodegradable plastic-binding peptides (PBPs) offer a potential solution through targeted adsorption and subsequent MP detection or removal from the environment. A challenge in discovering plastic-binding peptides is the vast combinatorial space of possible peptides (, over 10 for 12-mer peptides), which far exceeds the sample sizes typically reachable by experiments or biophysics-based computational methods.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!